Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.

Lung cancer (Amsterdam, Netherlands) - 1 Jun 2008

Yang Chih-Hsin

Abstract excerpt

Treatment with one of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib has become an additional option for patients with non-small cell lung cancer (NSCLC). Further investigation clearly demonstrated that a subset of patients show a better respo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asia, Eastern
Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Survival Analysis

Source

Identifiers

PMID: 18513581
DOI: 10.1016/S0169-5002(08)70102-8

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-18513581-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.PMID 18513581Read ↗

Overview of gefitinib in non-small cell lung cancer: an Asian perspective.Semantic proximity Read ↗

East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues.Semantic proximity Read ↗

Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.Semantic proximity Read ↗

EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations.Semantic proximity Read ↗

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach.Semantic proximity Read ↗

Emerging paradigms in targeted treatments for Asian patients with NSCLC.Semantic proximity Read ↗

Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.Semantic proximity Read ↗

Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.Semantic proximity Read ↗

Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.Semantic proximity Read ↗

Asiatic Acid from Centella asiatica as a Potent EGFR Tyrosine Kinase Inhibitor with Anticancer Activity in NSCLC Cells Harboring Wild-Type and T790M-Mutated EGFR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.